Journal Article

DZNE-2022-00378

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png A Bayesian perspective on Biogen's aducanumab trial.

Temp, A. G. M. (First author)DZNE* ; Ly, A. ; van Doorn, J. ; Wagenmakers, E.-J. ; Tang, Y. ; Lutz, M. W. ; Teipel, S. (Last author)DZNE*

2022
Wiley Hoboken, NJ

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/alz.12615

Abstract: This perspective is a companion to a recent editorial on the use of Bayesian analysis in clinical research. We aim to introduce and highlight the relevance and advantages that Bayesian inference offers to clinical trials using the data on the amyloid antibody aducanumab presented at a Food and Drug Administration hearing in November 2020 as an applied example. We apply Bayesian analysis of model plausibility and effect sizes based on simulated data of the two phase 3 trials of aducanumab in prodromal and mild dementia stages of Alzheimer's disease (AD). Bayesian analysis can quantify evidence in favor of, or against, the presence of an effect (i.e., provide evidence of absence), as well as assess the strength of the effect. This is in contrast to the binary conclusions provided by frequentist tests.

Keyword(s): Humans (MeSH) ; Alzheimer Disease: drug therapy (MeSH) ; Amyloid (MeSH) ; Amyloid beta-Peptides (MeSH) ; Antibodies, Monoclonal, Humanized: therapeutic use (MeSH) ; Bayes Theorem (MeSH) ; Clinical Trials, Phase III as Topic (MeSH) ; Alzheimer's disease ; Bayesian statistics ; aducanumab ; clinical trials

Note: (CC BY-NC-ND)

---

Contributing Institute(s):

1. Clinical Dementia Research Rostock /Greifswald (AG Teipel)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2022

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 15 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---